MA44611A - Compositions de composés hydrophobes cristallisés et leurs procédés de préparation et d'utilisation - Google Patents
Compositions de composés hydrophobes cristallisés et leurs procédés de préparation et d'utilisationInfo
- Publication number
- MA44611A MA44611A MA044611A MA44611A MA44611A MA 44611 A MA44611 A MA 44611A MA 044611 A MA044611 A MA 044611A MA 44611 A MA44611 A MA 44611A MA 44611 A MA44611 A MA 44611A
- Authority
- MA
- Morocco
- Prior art keywords
- hydrophobic
- compositions
- preparation
- use methods
- crystallized compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002209 hydrophobic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662317831P | 2016-04-04 | 2016-04-04 | |
US201662318208P | 2016-04-04 | 2016-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA44611A true MA44611A (fr) | 2019-02-13 |
Family
ID=58549290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA044611A MA44611A (fr) | 2016-04-04 | 2017-04-04 | Compositions de composés hydrophobes cristallisés et leurs procédés de préparation et d'utilisation |
Country Status (6)
Country | Link |
---|---|
US (2) | US20190083495A1 (fr) |
EP (1) | EP3440061A1 (fr) |
JP (1) | JP2019513723A (fr) |
CA (1) | CA3019950A1 (fr) |
MA (1) | MA44611A (fr) |
WO (2) | WO2017176792A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013070324A1 (fr) | 2011-11-07 | 2013-05-16 | University Of Louisville Research Foundation, Inc. | Compositions de microvésicules dérivées de plante comestible pour le diagnostic et le traitement d'une maladie |
WO2017176792A1 (fr) | 2016-04-04 | 2017-10-12 | Massachusetts Institute Of Technology | Méthodes de prévention ou de réduction d'une réponse fibrotique l'aide d'inhibiteurs de la csf1r |
AU2019230001A1 (en) * | 2018-03-05 | 2020-09-24 | Massachusetts Eye And Ear Infirmary | Amelioration of autoimmune uveitis through blockade of CSF1R |
CN111548343B (zh) * | 2018-06-01 | 2021-06-01 | 杭州阿诺生物医药科技有限公司 | 一种高活性csf1r抑制剂化合物的制备方法 |
UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
WO2021144360A1 (fr) * | 2020-01-17 | 2021-07-22 | F. Hoffmann-La Roche Ag | Inhibiteurs csf-1r à petites molécules en utilisations thérapeutiques et cosmétiques |
CN111956601B (zh) * | 2020-08-17 | 2022-08-02 | 中国医学科学院整形外科医院 | 一种抗瘢痕生物材料、制备方法及其用途 |
WO2022040606A1 (fr) * | 2020-08-20 | 2022-02-24 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Compositions et méthodes pour réduire la neuroinflammation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040002145A1 (en) * | 2002-03-18 | 2004-01-01 | Shewchuk Lisa Marie | Crystal structure of liganded cFMS kinase domain |
WO2009058801A1 (fr) | 2007-11-02 | 2009-05-07 | Janssen Pharmaceutica, N.V. | Utilisation d'inhibiteur cfms pour le traitement ou la prévention du cancer des os et de la perte osseuse et de la douleur osseuse associées au cancer des os |
PT2766359T (pt) | 2011-10-14 | 2016-07-14 | Ambit Biosciences Corp | Compostos heterocíclicos e utilização dos mesmos como moduladores de recetores tirosina-cinase de tipo iii |
US20160040142A1 (en) | 2013-02-28 | 2016-02-11 | University Court Of The University Of Edinburgh | Csf1 therapeutics |
EP2970905B1 (fr) | 2013-03-15 | 2019-10-16 | Stemcell Technologies Inc. | Compositions et procédés pour obtenir des cultures de cellules souches mésenchymateuses enrichies |
GB201315486D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
US10426735B2 (en) | 2014-08-01 | 2019-10-01 | Massachusetts Institute Of Technology | Modified alginates for anti-fibrotic materials and applications |
WO2017176792A1 (fr) | 2016-04-04 | 2017-10-12 | Massachusetts Institute Of Technology | Méthodes de prévention ou de réduction d'une réponse fibrotique l'aide d'inhibiteurs de la csf1r |
-
2017
- 2017-04-04 WO PCT/US2017/025991 patent/WO2017176792A1/fr active Application Filing
- 2017-04-04 EP EP17718264.9A patent/EP3440061A1/fr not_active Withdrawn
- 2017-04-04 US US16/081,654 patent/US20190083495A1/en not_active Abandoned
- 2017-04-04 CA CA3019950A patent/CA3019950A1/fr not_active Abandoned
- 2017-04-04 US US16/091,330 patent/US10851069B2/en active Active
- 2017-04-04 MA MA044611A patent/MA44611A/fr unknown
- 2017-04-04 WO PCT/US2017/026009 patent/WO2017176804A1/fr active Application Filing
- 2017-04-04 JP JP2018551986A patent/JP2019513723A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3019950A1 (fr) | 2017-10-12 |
WO2017176792A1 (fr) | 2017-10-12 |
US10851069B2 (en) | 2020-12-01 |
US20190083495A1 (en) | 2019-03-21 |
JP2019513723A (ja) | 2019-05-30 |
US20190210976A1 (en) | 2019-07-11 |
WO2017176804A1 (fr) | 2017-10-12 |
EP3440061A1 (fr) | 2019-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44611A (fr) | Compositions de composés hydrophobes cristallisés et leurs procédés de préparation et d'utilisation | |
MA50045A (fr) | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci | |
MA41999A (fr) | Compositions d'acide obéticholique et procédés d'utilisation | |
MA49045A (fr) | Compositions et procédés destinés à la distribution régulée d'acide | |
MA54252A (fr) | Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation | |
MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA48779A (fr) | Formes cristallines d'inhibiteur de fgfr et leurs procédés de préparation | |
MA46905A (fr) | Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides | |
MA52494A (fr) | Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation | |
MA45688A (fr) | Compositions et procédés de potentialisation d'agents antimicrobiens | |
MA43822A (fr) | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides | |
MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
MA50041A (fr) | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci | |
MA49752A (fr) | Procédés de préparation de composés de pyrrolidine | |
MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA47167A (fr) | Composés pyrazolopyrimidine et leurs procédés d'utilisation | |
MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA42409A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA46546A (fr) | Composés thérapeutiques et leurs procédés d'utilisation | |
MA42055A (fr) | Composés antimicrobiens et procédés de fabrication et d'utilisation de ceux-ci | |
MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA49560A (fr) | Composés cétoniques bicycliques et leurs procédés d'utilisation | |
MA48942A (fr) | Composés thérapeutiques, compositions et procédés d'utilisation associés |